Overexpression of cell cycle progression inhibitor Geminin is associated with tumor stem-like phenotype of triple-negative breast cancer

Journal of Breast Cancer

Volumn 15, Issue 2, 2012, Pages 162-171

  Di Bonito, Maurizio ^a   Cantile, Monica ^a   Collina, Francesca ^a   Scognamiglio, Giosuè ^a   Cerrone, Margherita ^a   La Mantia, Elvira ^a   Barbato, Antonio ^a   Liguori, Giuseppina ^a   Botti, Gerardo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CD133 antigen; GMNN protein; Triple negative breast cancer

Indexed keywords

CD133 ANTIGEN; GEMININ; KI 67 ANTIGEN; MESSENGER RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE PROGRESSION; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84865107258     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.2.162     Document Type: Article

References (29)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98: 10869-74.
2. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
3. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14: 1368-76.
4. Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12 Suppl 2:S3.
5. Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 2009;113:411-22.
6. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triplenegative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010;23:123-33.
7. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.
8. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24-phenotype is enriched in basallike breast tumors. Breast Cancer Res 2008;10:R53.
9. Arnes JB, Collett K, Akslen LA. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008;52:370-80.
10. Chaffer CL, Weinberg RA. Cancer cell of origin: spotlight on luminal progenitors. Cell Stem Cell 2010;7:271-2.
11. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302-13.
12. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888.
13. Takeda DY, Dutta A. DNA replication and progression through S phase. Oncogene 2005;24:2827-43.
14. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 2004;204:121-30.
15. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005;11: 2510-7.
16. Dudderidge TJ, McCracken SR, Loddo M, Fanshawe TR, Kelly JD, Neal DE, et al. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 2007;96:1384-93.
17. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med 2008;37:309-18.
18. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, et al. Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer 2007;109:949-56.
19. Zhu W, Depamphilis ML. Selective killing of cancer cells by suppression of geminin activity. Cancer Res 2009;69:4870-7.
20. Shomori K, Nishihara K, Tamura T, Tatebe S, Horie Y, Nosaka K, et al. Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer 2010;13:177-85.
21. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 2009;100: 1128-34.
22. Montanari M, Boninsegna A, Faraglia B, Coco C, Giordano A, Cittadini A, et al. Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors. J Cell Physiol 2005;202:215-22.
23. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16:6159-68.
24. Mimeault M, Batra SK. New promising drug targets in cancer-and metastasis-initiating cells. Drug Discov Today 2010;15:354-64.
25. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
26. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009;18:1127-34.
27. Cho DY, Lin SZ, Yang WK, Hsu DM, Lin HL, Lee HC, et al. The role of cancer stem cells (CD133(+) in malignant gliomas. Cell Transplant 2011;20:121-5.
28. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J (Engl) 2009;122:2763-9.
29. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 2011;102:1107-11.